BI’s Article search uses Boolean search capabilities. If you are not familiar with these principles, here are some quick tips.
To search specifically for more than one word, put the search term in quotation marks. For example, “workers compensation”. This will limit your search to that combination of words.
To search for a combination of terms, use quotations and the & symbol. For example, “hurricane” & “loss”.
Reprints
The recent Food and Drug Administration approval of Biogden's Aduhelm, a drug that may slow Alzheimer's conditions, has raised concerns that patient advocacy groups will pressure Medicare and private insurers to cover expensive tests needed to concretely diagnose the disease, Politico reports. Other questions include whether patients will face huge out-of-pocket costs, as well as how successful the drug will be in treating Alzheimer's.
1. UnitedHealth reports significant data breach; personal health info compromised
2. Humana to cut Medicare Advantage benefits amid rising costs
3. Walmart to shut down health clinics due to unprofitability
4. UnitedHealth faces scrutiny over size, operations, and cyberattack
5. UnitedHealth to close Optum Virtual Care amid telehealth decline
6. Cigna writes off $1.8 billion from VillageMD investment amid losses